Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-10 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-712 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 |
filingDate |
2020-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee565c0d45084494f44d19e64bc0e9dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08c63baaf39b70d8e26017bed9f01550 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1d525037656a6722c8211c670ac49c9 |
publicationDate |
2021-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2021076645-A1 |
titleOfInvention |
Treatment of airway conditions by modulation of mir200 family micrornas |
abstract |
The inventions provide the art with novel treatments of various airway conditions such as asthma wherein pathological production of mucus is implicated. Disclosed are novel inhibitors of miR-200 micro-RNAs, including inhibitors of miR-141. These miRNAs promote pathological mucus production and other airway dysfunction. They may be targeted by antagomirs which disrupt their activity. Additionally, they may be targeted by compositions with disrupt the gene expression of the targeted miR. |
priorityDate |
2019-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |